![[Video] The Weekly Break Out Ep. 20: Pacific policy in Singapore and the UK’s new defense plan](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/Break-Out-ep-20-thumb-Play-Button.jpg?#)
STAT+: Sanofi to buy Blueprint Medicines in deal worth more than $9 billion
Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline
LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.
Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday. It’s also offering potential milestone payments worth up to $400 million based on development and regulatory successes for the experimental drug BLU-808, which is being tested in a number of allergic and inflammatory diseases.
Blueprint, based in Cambridge, Mass., has an approved drug called Ayvakit that treats a rare immunological condition called systemic mastocytosis. It brought in $479 million in revenue in 2024, with Blueprint forecasting that sales of the drug could reach $2 billion by 2030.
